ArticleAnnals of dermatology2018

Economic Burden Can Be the Major Determining Factor Resulting in Short-Term Intermittent and Repetitive Ustekinumab Treatment for Moderate-to-Severe Psoriasis.

Chong Won Choi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.